New York, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) — Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has appointed a leading orthopedic physician scientist recognized for his work in orthobiologics and regenerative medicine, Dr. Tsun “Sean” Law, MD, MBA as its Chief Executive Officer.
Dr. Law will lead the Company’s efforts to develop and advance an integrated platform of exosome-based therapies, topical plant-derived formulations, injectable hydrogel-exosome candidates, and exosomal biomarker panels designed to address a broad spectrum of patient needs and therapeutic goals.
Dr. Law is a South Florida–based orthopedic medicine physician scientist specializing in hip and knee osteoarthritis, with a focus on orthobiologics and regenerative medicine. He serves as Director of Clinical Research at HSS Florida, where he leads studies on orthobiologic therapies, such as microfragmented adipose tissue, aiming to enhance treatment options for osteoarthritis. Dr. Law has been featured in Medscape, where he discussed the current landscape and challenges of orthobiologic treatments.
Figure 1 – Human Continuum Inc. Appoints Dr. Tsun “Sean” Law, MD, MBA as its Chief Executive Officer.
“Health and longevity have always been essential priorities, and it’s clear that more people today are taking a proactive interest in both,” said Dr. Sean Law, MD, MBA, Chief Executive Officer and Board Member of Human Continuum. “Exosome-based therapies represent an important next step in advancing wellness and recovery, regardless of age. Exosomes, like those being developed by Human Continuum, have shown meaningful potential in easing chronic symptoms and improving outcomes for a range of common injuries and conditions. The next challenge lies in their accessibility, and we are aiming to meet this challenge head on, making these treatments available, affordable, and scalable beyond the research setting to the benefit of all.”
Dr. Law’s research spans the integration of robotic and sensor technologies in orthopedic care to orthobiologics in regenerative medicine. His work has been published in numerous peer-reviewed journals and presented at both national and international conferences.
Musculoskeletal diseases affect more than 60 million adults in the United States, including arthritis, osteoporosis, back pain, and other degenerative or inflammatory conditions. Our platelet-derived exosome infusion harnesses the regenerative signaling of stem cells, without the cells themselves, offering a minimally invasive, scalable, and standardized approach for systemic rejuvenation and inflammation control.